Cancer

logo
Address

The National Institute for Biotechnology
in the Negev Ltd.
Ben-Gurion University of the Negev

close icon

Research Field

Prof. Peled and his colleagues are developing a novel targeted therapy for exon-20 EGFR mutated lung cancer based on the fact that the structure of EGFR has been studied extensively. Prof. Peled and his team are using molecular dynamics simulations and quantum mechanical methods to employ small molecules (NCE) with the aim of intelligently designing novel molecules for inhibiting the TK domain of insensitive mutated EGFR.

Prof. Nir Peled, MD, PhD

Lung cancer is the leading cause of cancer-related death worldwide, with more than 1.7 million deaths per year. Prof. Peled focuses on the wide translational and clinical perspectives of lung cancer, including personalized targeted therapy in lung cancer, biomarker development, immuno-oncology, and early detection of this disease. 

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used to treat a variety of cancers including non-small cell lung cancer. Response to tyrosine kinase inhibitors in lung cancer can be subdivided into two groups. The first group, in which treatment can be very successful, includes patients carrying sensitizing EGFR mutations in their tumors. The second group of patients presents primary mutations in EGFR that do not respond to treatment with TKIs; most of these patients have primary in frame insertion resistance mutations to TKIs in exon 20 of EGFR; this accounts for approximately 10% of all cases of EGFR mutations (around 30,000 cases per year). Currently, there is no approved treatment for this group of patients, and this represents a very strong unmet medical need in the area of lung cancer treatment.

 

Read More

Publications

See Full Publication List